» Articles » PMID: 29665812

Effects of Statin Therapy on Chronic Kidney Disease Patients with Coronary Artery Disease

Overview
Publisher Biomed Central
Date 2018 Apr 19
PMID 29665812
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Long-term persistence of statin therapy provided an ongoing reduction in mortality among patients with and without a known history of CVD, and renoprotective effect on CKD patients. Until now, very few reports are available from China to address the effects of statin therapy in CKD + CAD patients.

Methods: We compared the effects of long-term statin therapy (follow-up time 4 years) in terms of cardiovascular events, all-cause death, and cardiac death among 254 CKD patients with or without CAD.

Results: Long-term statin therapy was much more effective in the CKD + CAD patients compared with CKD patients. In the CAD + CKD patients, long-term statins showed a 22.2% reduction in the CVs rate (P = 0.012). With regard to the all-cause and cardiac deaths, long-term statins had significant treatment effects on the CAD + CKD patients (reduction of about 28.1% in mortality rates, P < 0.001). In contrast, long-term statin therapy exerted no significant influence on the clinical outcomes of the CKD-only patients.

Conclusion: Long-term statin therapy more dramatically reduced the CVs and mortality rates of the CKD patients with concomitant CAD. In contrast, CKD-only patients had a good prognosis and did not appear to require statin treatment.

Citing Articles

Impact of atorvastatin reload on the prevention of contrast-induced nephropathy in patients on chronic statin therapy: A prospective randomized trial.

Hammami R, Masmoudi O, Jdidi J, Turki M, Charfi R, Ben Mrad I PLoS One. 2023; 18(5):e0270000.

PMID: 37155629 PMC: 10166561. DOI: 10.1371/journal.pone.0270000.


Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease.

Mathew R, Rosenson R, Lyubarova R, Chaudhry R, Costa S, Bangalore S Cardiovasc Drugs Ther. 2020; 35(3):479-489.

PMID: 32556851 DOI: 10.1007/s10557-020-07020-x.


The impact of dyslipidemia and oxidative stress on vasoactive mediators in patients with renal dysfunction.

Jabarpour M, Rashtchizadeh N, Argani H, Ghorbanihaghjo A, Ranjbarzadhag M, Sanajou D Int Urol Nephrol. 2019; 51(12):2235-2242.

PMID: 31641998 DOI: 10.1007/s11255-019-02319-7.


The effect of chronic kidney disease on lipid metabolism.

Dincer N, Dagel T, Afsar B, Covic A, Ortiz A, Kanbay M Int Urol Nephrol. 2018; 51(2):265-277.

PMID: 30519980 DOI: 10.1007/s11255-018-2047-y.

References
1.
Shepherd J, Kastelein J, Bittner V, Deedwania P, Breazna A, Dobson S . Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007; 2(6):1131-9. DOI: 10.2215/CJN.04371206. View

2.
Briasoulis A, Bakris G . Chronic kidney disease as a coronary artery disease risk equivalent. Curr Cardiol Rep. 2013; 15(3):340. DOI: 10.1007/s11886-012-0340-4. View

3.
Liu X, Zhang S, Liu M, Wang Y, Wu J, Dong Q . Chinese guidelines for endovascular management of ischemic cerebrovascular diseases. Interv Neurol. 2014; 1(3-4):171-84. PMC: 4031784. DOI: 10.1159/000351688. View

4.
Chodick G, Shalev V, Gerber Y, Heymann A, Silber H, Simah V . Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther. 2008; 30(11):2167-79. DOI: 10.1016/j.clinthera.2008.11.012. View

5.
Fang C, Li J, Hui R . Statin, like aspirin, should be given as early as possible in patients with acute coronary syndrome. Med Hypotheses. 2004; 64(1):192-6. DOI: 10.1016/j.mehy.2004.06.018. View